# Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma

> **NCT07281664** · NA · NOT_YET_RECRUITING · sponsor: **Third Affiliated Hospital, Sun Yat-Sen University** · enrollment: 30 (estimated)

## Conditions studied

- Hepatocellular Carcinoma
- Transarterial Chemoembolization

## Interventions

- **PROCEDURE:** Transarterial chemoembolization (TACE)
- **DRUG:** bevacizumab and atezolizumab

## Key facts

- **NCT ID:** NCT07281664
- **Lead sponsor:** Third Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2028-12-31
- **Final completion:** 2029-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07281664

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07281664, "Transarterial Chemoembolization With Low-Dose Bevacizumab Plus Atezolizumab as First-Line Treatment for Unresectable Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07281664. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*